<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077853</url>
  </required_header>
  <id_info>
    <org_study_id>PPET</org_study_id>
    <nct_id>NCT04077853</nct_id>
  </id_info>
  <brief_title>Progesterone in Expectantly Managed Early-onset Preeclampsia</brief_title>
  <official_title>Efficacy of 17-Hydroxyprogesterone Caproate in Expectantly Managed Early-onset Preeclampsia: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preeclampsia is a disorder of widespread vascular endothelial malfunction and vasospasm that
      occurs after 20 weeks' gestation and can present as late as 4-6 weeks postpartum
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently there is no effective treatment for early-onset preeclampsia except for early
      delivery of the fetus along with the placenta. Progesterone supplementation in the form of
      17-alpha-hydroxyprogesterone caproate (17-OHPC) is currently used obstetrically to prevent
      recurrent preterm birth in patients with pregnancies not complicated by preeclampsia.
      Previous studies reported that patients with severe PE had significantly lower serum
      progesterone concentrations than gestational age- and race-matched non-preeclamptics.
      Moreover, supplementation of placental ischemic rats with 17-OHPC decreased blood pressure,
      inflammatory cytokines, and ET-1 within 24 hours of treatment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean difference between blood pressure measurements in both groups</measure>
    <time_frame>one month</time_frame>
    <description>blood pressure measured by mercury sphygmomanometer</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>women will be given 17-OHPC 250 mg intra-muscular at admission and every 7 days thereafter in addition to other conservative measures of early-onset PE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention will be given apart from the usual conservative measures of early-onset PE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17 Hydroxyprogesterone Capronate</intervention_name>
    <description>Intramuscular injection 250 mg</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age between 20+0 and 33+6 weeks.

          -  Singleton pregnancy.

          -  Willing to participate in the study and sign the informed consent.

        Exclusion Criteria:

          -  Maternal compromise requiring emergent delivery (ongoing placental abruption, DIC,
             pulmonary edema).

          -  Fetal compromise requiring emergent delivery (fetal bradycardia, recurrent late fetal
             heart rate decelerations).

          -  Platelet count &lt; 100,000/microliter (thrombocytopenia) with evidence of HELLP
             syndrome;

          -  Persistently abnormal hepatic enzyme concentrations (twice or more upper normal
             values);

          -  Severe fetal growth restriction (ultrasound-estimated fetal weight less than fifth
             percentile);

          -  Severe Oligohydramnios (AFI &lt; 5cm)

          -  Reversal of end diastolic flow(REDF) in umbilical artery Doppler testing;

          -  Eclampsia;

          -  Nonreassuring fetal status during daily testing (biophysical profile &lt;4/10 and/or
             recurrent variable or late decelerations);

          -  Intrauterine fetal death.

          -  Patient is unable or unwilling to give consent.

          -  Patients currently using progesterone for other indications.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ahmed Abbas</name>
      <address>
        <city>Assiut</city>
        <state>Cairo</state>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ahmed abbas, MD</last_name>
      <phone>00201003385183</phone>
      <email>bmr90@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>ahmed abbas</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 1, 2019</study_first_submitted>
  <study_first_submitted_qc>September 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Abbas</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>17 alpha-Hydroxyprogesterone Caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

